ATE418977T1 - Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung - Google Patents

Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung

Info

Publication number
ATE418977T1
ATE418977T1 AT06736775T AT06736775T ATE418977T1 AT E418977 T1 ATE418977 T1 AT E418977T1 AT 06736775 T AT06736775 T AT 06736775T AT 06736775 T AT06736775 T AT 06736775T AT E418977 T1 ATE418977 T1 AT E418977T1
Authority
AT
Austria
Prior art keywords
treatment
von hippel
production
lindau disease
phenylacetyl
Prior art date
Application number
AT06736775T
Other languages
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of ATE418977T1 publication Critical patent/ATE418977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06736775T 2005-03-08 2006-03-02 Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung ATE418977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65975905P 2005-03-08 2005-03-08

Publications (1)

Publication Number Publication Date
ATE418977T1 true ATE418977T1 (de) 2009-01-15

Family

ID=36691615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736775T ATE418977T1 (de) 2005-03-08 2006-03-02 Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung

Country Status (6)

Country Link
US (1) US20060205818A1 (de)
EP (1) EP1855665B1 (de)
AT (1) ATE418977T1 (de)
DE (1) DE602006004568D1 (de)
EA (1) EA012908B1 (de)
WO (1) WO2006096481A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2635539C2 (ru) * 2016-03-10 2017-11-13 Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук Полимерные водорастворимые производные 4-фенил-бутановой кислоты, обладающие противоопухолевой активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559325A (en) * 1981-12-15 1985-12-17 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US6037376A (en) * 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
US5391575A (en) * 1994-05-04 1995-02-21 Burzynski; Stanislaw R. Method for treating neurofibromatosis
US6013278A (en) * 1996-05-14 2000-01-11 Burzynski Research Institute Liposomal antineoplaston therapies with markedly improved antineoplastic activity
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
BR9916407A (pt) * 1998-12-21 2001-09-25 Univ Monash Detecção e tratamento de doenças dos rins
KR20020068261A (ko) * 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
AU2002303892A1 (en) * 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors

Also Published As

Publication number Publication date
DE602006004568D1 (de) 2009-02-12
EP1855665A1 (de) 2007-11-21
EA200701920A1 (ru) 2008-02-28
EP1855665B1 (de) 2008-12-31
US20060205818A1 (en) 2006-09-14
WO2006096481A1 (en) 2006-09-14
EA012908B1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
DE602004019198D1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE418977T1 (de) Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung
ATE445394T1 (de) Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE491443T1 (de) Verwendung des agomelatins zur herstellung eines medikamentes zur behandlung der bipolaren erkrankungen
DE502006004735D1 (de) Mittel zur behandlung von infektionen
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
DE602006019842D1 (de) Verwendung von lecithin als arzneimittel zur behandlung von psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties